More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.59B
EPS
4.8
P/E ratio
15.6
Price to sales
1.73
Dividend yield
--
Beta
0.451969
Previous close
$70.89
Today's open
$69.98
Day's range
$69.75 - $70.93
52 week range
$67.14 - $87.76
show more
CEO
Nikhil Lalwani
Employees
970
Headquarters
Princeton, NJ
Exchange
NASDAQ Global Market
Shares outstanding
22718931
Issue type
Common Stock
Healthcare
Pharmaceuticals
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Investment Research • Nov 17, 2026

ANI Pharmaceuticals, Inc. (ANIP) Q3 2026 Earnings Call Transcript
ANI Pharmaceuticals, Inc. ( ANIP ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Irina Rivkind Koffler - Vice President of Investor Relations Nikhil Lalwani - President, CEO & Director Mary Pao - Chief Medical Officer Christopher Mutz - Senior Vp & Head of Rare Disease Stephen Carey - Senior VP of Finance & CFO Conference Call Participants Vamil Divan - Guggenheim Securities, LLC, Research Division Yuchen Ding - Jefferies LLC, Research Division Ekaterina Knyazkova - JPMorgan Chase & Co, Research Division Gary Nachman - Canaccord Genuity Corp., Research Division Daniel Christopher Clark - Leerink Partners LLC, Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, everyone, and welcome to today's ANI Pharmaceuticals, Inc. Third Quarter 2026 Earnings Results Conference Call.
Seeking Alpha • Nov 7, 2026

ANI Pharmaceuticals Q3 Earnings Call Highlights
ANI Pharmaceuticals NASDAQ: ANIP reported 28% revenue growth for the third quarter of 2026 and announced an offer to acquire Egetis Therapeutics for $560 million in equity value, while lowering its full-year sales outlook for Cortrophin Gel after pharmacy bottlenecks slowed the conversion of new patient cases into treatment.
MarketBeat • Nov 5, 2026

ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business
PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announces a recommended public offer to acquire Egetis Therapeutics AB (publ) (“Egetis”) (the “Offer”).
GlobeNewsWire • Nov 5, 2026

REPEAT – ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business
PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announces a recommended public offer to acquire Egetis Therapeutics AB (publ) (“Egetis”) (the “Offer”).
GlobeNewsWire • Nov 5, 2026

ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results
PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the third quarter ended September 30, 2026.
GlobeNewsWire • Nov 5, 2026

ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue Estimates
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $2.7 per share, beating the Zacks Consensus Estimate of $2.17 per share. This compares to earnings of $2.04 per share a year ago.
Zacks Investment Research • Nov 5, 2026

ANI (ANIP) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks Investment Research • Nov 5, 2026

ANI Pharmaceuticals to Present at Upcoming November Investor Conferences
PRINCETON, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company's executive leadership team, will participate in presentations and fireside chats at the following upcoming investor conferences:
GlobeNewsWire • Nov 3, 2026

ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET
PRINCETON, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its third quarter 2026 financial results on Thursday, November 5, 2026, at 8:00 a.m. ET.
GlobeNewsWire • Oct 23, 2026

¹ Disclosures

Open an M1 investment account to buy and sell ANI Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.